tofacitinib
pfizer
['tofa']
#abst0405 #acr22 post hoc of ph2/3 trials tofa for as: aes/saes in pts w/bmi &lt; 25 kg/m2 vs other bmi categories. most frequent aes ( 5% of pts) nasopharyngitis, uri&amp; arthralgia. from bl in lfts similar, while % change from bl in lipid levels in tofa vs pbo pts 
Rheumatologist at Scarsdale Medical Group, Runner, Traveler Opinions are my own